Literature DB >> 19048202

Interferons and their use in persistent viral infections.

Stéphane Chevaliez1, Jean-Michel Pawlotsky.   

Abstract

In 2007, the world celebrated the 50th anniversary of the discovery of interferon (IFN) by Isaacs and Lindenmann. Subsequently, the IFN-alpha gene was cloned, fully sequenced and IFN-alpha was produced in recombinant form. Recombinant IFN-alpha is now used as the basis for treatment of chronic hepatitis C virus infection and can also be used to treat certain forms of chronic hepatitis B virus infections. IFNs have also been used in other viral infections, although with less success. The antiviral mechanisms of IFNs are reviewed in this chapter as well as the utility of IFNs in the treatment of persistent viral infections.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19048202      PMCID： PMC7114994          DOI： 10.1007/978-3-540-79086-0_8

Source DB:  PubMed          Journal:  Handb Exp Pharmacol        ISSN： 0171-2004


  186 in total

1.  High viral eradication with a daily 12-week natural interferon-beta treatment regimen in chronic hepatitis C patients with low viral load. IFN-beta Research Group.

Authors:  Y Shiratori; R Nakata; N Shimizu; H Katada; S Hisamitsu; E Yasuda; M Matsumura; T Narita; K Kawada; M Omata
Journal:  Dig Dis Sci       Date:  2000-12       Impact factor: 3.199

Review 2.  Treatment of hepatitis D.

Authors:  G A Niro; F Rosina; M Rizzetto
Journal:  J Viral Hepat       Date:  2005-01       Impact factor: 3.728

3.  Peg-interferon improves liver histology in patients with HBeAg-positive chronic hepatitis B: no additional benefit of combination with lamivudine.

Authors:  Monika van Zonneveld; Pieter E Zondervan; Yilmaz Cakaloglu; Christopher Simon; Ulus S Akarca; Thomas M K So; Hajo J Flink; Robert A de Man; Solko W Schalm; Harry L A Janssen
Journal:  Liver Int       Date:  2006-05       Impact factor: 5.828

4.  Treatment of chronic non-A,non-B hepatitis with recombinant human alpha interferon. A preliminary report.

Authors:  J H Hoofnagle; K D Mullen; D B Jones; V Rustgi; A Di Bisceglie; M Peters; J G Waggoner; Y Park; E A Jones
Journal:  N Engl J Med       Date:  1986-12-18       Impact factor: 91.245

Review 5.  IFN-tau: a novel subtype I IFN1. Structural characteristics, non-ubiquitous expression, structure-function relationships, a pregnancy hormonal embryonic signal and cross-species therapeutic potentialities.

Authors:  J L Martal; N M Chêne; L P Huynh; R M L'Haridon; P B Reinaud; M W Guillomot; M A Charlier; S Y Charpigny
Journal:  Biochimie       Date:  1998 Aug-Sep       Impact factor: 4.079

6.  Immunomodulatory activities of IFN-gamma1b in combination with type I IFN: implications for the use of IFN-gamma1b in the treatment of chronic HCV infections.

Authors:  Tony Wang; Lawrence M Blatt; Scott D Seiwert
Journal:  J Interferon Cytokine Res       Date:  2006-07       Impact factor: 2.607

7.  A short course of pegylated interferon-alpha in acute HCV hepatitis.

Authors:  G Calleri; G Cariti; F Gaiottino; F G De Rosa; O Bargiacchi; S Audagnotto; S Quaglia; T De Blasi; P Romano; A Traverso; G Leo; R Carbone; B Del Mastro; M Tinelli; P Caramello; G Di Perri
Journal:  J Viral Hepat       Date:  2007-02       Impact factor: 3.728

8.  Inhibition of hepatitis B virus DNA replicative intermediate forms by recombinant interferon-gamma.

Authors:  Mohammad-Khalid Parvez; Deepak Sehgal; Shiv-Kumar Sarin; Seemi-Farhat Basir; Shahid Jameel
Journal:  World J Gastroenterol       Date:  2006-05-21       Impact factor: 5.742

9.  Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir.

Authors:  Christoph Sarrazin; Tara L Kieffer; Doug Bartels; Brian Hanzelka; Ute Müh; Martin Welker; Dennis Wincheringer; Yi Zhou; Hui-May Chu; Chao Lin; Christine Weegink; Henk Reesink; Stefan Zeuzem; Ann D Kwong
Journal:  Gastroenterology       Date:  2007-02-21       Impact factor: 22.682

10.  Zidovudine plus interferon-alpha versus zidovudine alone in HIV-infected symptomatic or asymptomatic persons with CD4+ cell counts > 150 x 10(6)/L: results of the Zidon trial. Zidon Study Group.

Authors:  E Fernández-Cruz; J M Lang; J Frissen; V Furner; M Châteauvert; C A Boucher; P Dowd; J Stevens
Journal:  AIDS       Date:  1995-09       Impact factor: 4.177
View more
  7 in total

1.  Therapeutic implications of hepatitis C virus resistance to antiviral drugs.

Authors:  Jean-Michel Pawlotsky
Journal:  Therap Adv Gastroenterol       Date:  2009-07       Impact factor: 4.409

2.  Exosomes mediate the cell-to-cell transmission of IFN-α-induced antiviral activity.

Authors:  Jianhua Li; Kuancheng Liu; Yang Liu; Yan Xu; Fei Zhang; Huijuan Yang; Jiangxia Liu; Tingting Pan; Jieliang Chen; Min Wu; Xiaohui Zhou; Zhenghong Yuan
Journal:  Nat Immunol       Date:  2013-07-07       Impact factor: 25.606

3.  The evolution of the major hepatitis C genotypes correlates with clinical response to interferon therapy.

Authors:  Phillip S Pang; Paul J Planet; Jeffrey S Glenn
Journal:  PLoS One       Date:  2009-08-11       Impact factor: 3.240

4.  Hepatitis C variability, patterns of resistance, and impact on therapy.

Authors:  Cristina Simona Strahotin; Michael Babich
Journal:  Adv Virol       Date:  2012-07-19

5.  Susceptibility of different hepatitis B virus isolates to interferon-alpha in a mouse model based on hydrodynamic injection.

Authors:  Jingjiao Song; Yun Zhou; Sheng Li; Baoju Wang; Xin Zheng; Jun Wu; Kathrin Gibbert; Ulf Dittmer; Mengji Lu; Dongliang Yang
Journal:  PLoS One       Date:  2014-03-11       Impact factor: 3.240

Review 6.  Zika Virus Pathogenesis: A Battle for Immune Evasion.

Authors:  Judith Estévez-Herrera; Silvia Pérez-Yanes; Romina Cabrera-Rodríguez; Daniel Márquez-Arce; Rodrigo Trujillo-González; José-David Machado; Ricardo Madrid; Agustín Valenzuela-Fernández
Journal:  Vaccines (Basel)       Date:  2021-03-22

7.  What are the pros and cons of the use of host-targeted agents against hepatitis C?

Authors:  Jean-Michel Pawlotsky
Journal:  Antiviral Res       Date:  2014-02-26       Impact factor: 5.970
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.